Personalized medicine network for childhood arthritis and rheumatic disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

UCAN CAN-DU is a multicenter observational cohort initiative aimed at understanding juvenile idiopathic arthritis (JIA) through the collection of biological samples, clinical data, and patient-reported outcomes from children diagnosed with the condition. The study seeks to develop predictive tests that can guide the selection and timing of biologic therapies, which are effective but can have serious side effects and high costs. Additionally, it incorporates a health economics component to evaluate the socioeconomic impact of biomarker-based treatments. Data will be managed through a secure cloud-computing service, allowing for real-time integration and analysis to enhance patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Cohort 1: - Biologic Basis of JIA

* ≤18 years\*
* Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment
* Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis

Cohort 2 - Start Biologics

* JIA diagnosis as per ILAR criteria (all subtypes)
* ≤18 years\*
* Active arthritis
* For sJIA, active disease not necessarily with arthritis.
* Time of start, restart or switch biologic therapy: e.g. failure, insufficient/partial response or intolerance

Cohort 3 - Stop Biologics

* JIA diagnosis as per ILAR criteria (all subtypes)
* ≤18 years\*
* Inactive disease
* Discontinuing/tapering biologics for inactive disease

Cohort 4: Extreme Phenotypes

* Unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations
* High suspicion of genetic contribution
* Severely affected patients with difficult to control disease (ie failure of multiple biologics)

Exclusion Criteria:

Cohort 1 :

* Arthritis explained by another diagnosis
* Joint injections as previous treatment less than 4 weeks prior to enrollment

Cohort 2:

* Arthritis explained by any other cause
* Start on biologics as an indication for uveitis only

Cohort 3:

\- Tapering scheme \> 12 months to complete biologics stop

Cohort 4:

\- Arthritis explained by another diagnosis

Where it's running

• Alberta Children's Hospital - University of Calgary
  Calgary, Alberta, Canada Recruiting
• Stollery Children's Hospital
  Edmonton, Alberta, Canada Recruiting
• BC Children's Hospital
  Vancouver, British Columbia, Canada Recruiting
• Children's Hospital Health Science Centre Winnipeg
  Winnipeg, Manitoba, Canada Recruiting
• Janeway Children's Hospital and Rehabilitation Centre
  St. John's, Newfoundland and Labrador, Canada Recruiting
• IWK Health Centre
  Halifax, Nova Scotia, Canada Recruiting

Study contacts

• Principal investigator: Rae SM Yeung, MD, PhD, FRCPC — The Hospital for Sick Children (SickKids), University of Toronto
• Study coordinator: Alexander Mosoiu
• Email: alexander.mosiu@sickkids.ca
• Phone: 416-813-7654

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using infrared cameras to help detect juvenile arthritis in kids

  This study tests whether infrared thermography can help identify joint inflammation in children with juvenile idiopathic arthritis compared with standard tests.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07914179

• Oral health, saliva bacteria, and disease activity in children with JIA

  This study checks if how active juvenile idiopathic arthritis is relates to oral health in children who already receive rheumatology care.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Pudongxinqu · NCT07799831

• Olokizumab treatment for children with polyarticular juvenile idiopathic arthritis

  This test gives weight-based doses of olokizumab every 4 weeks to see if it helps control polyarticular juvenile idiopathic arthritis and is safe for children aged 2–17.

  Recruiting at 14 sites Phase 2 R-Pharm · Kazan' and 13 other locations · NCT07517575

• Post-marketing surveillance of Cosentyx (secukinumab) for hidradenitis suppurativa, pediatric plaque psoriasis, and juvenile idiopathic arthritis in Korea

  This study will see how Cosentyx (secukinumab) works and is tolerated in people in Korea with moderate-to-severe hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis who are being treated in routine care.

  Recruiting Novartis · Seoul, Seoul · NCT07243782

• Understanding pain in juvenile idiopathic arthritis

  This project will test whether temperature and pressure pain tests, questionnaires, and blood or saliva samples can help explain pain in kids and teens (ages 9–17) with juvenile idiopathic arthritis.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07217782

• Follow-up care for new cases of polyarthritis in children and young adults

  This program will try standardized medical follow-up for children and young adults (≤50) with new-onset JIA, RA, psoriatic/seronegative/undifferentiated arthritis, SLE, or diffuse systemic sclerosis who are treatment-naïve or treated ≤3 months to see if more patients reach disease control or remission.

  Recruiting Université Catholique de Louvain · Brussels · NCT07000916

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.